Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cantor Fitzgerald
AstraZeneca
Farmers Insurance
Boehringer Ingelheim
Healthtrust
US Department of Justice
Citi
Johnson and Johnson

Generated: November 17, 2018

DrugPatentWatch Database Preview

Infliximab - Biologic Drug Details

« Back to Dashboard

Summary for infliximab
Tradenames:1
Patents:308
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for infliximab
Pharmacology for infliximab

US Patents for infliximab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Try a Free Trial Massachusetts Eye and Ear Infirmary (Boston, MA) ➤ Try a Free Trial RX Orphan search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Try a Free Trial UNIVERSITY OF TROMSO (Tromso, NO) ➤ Try a Free Trial RX Orphan search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Try a Free Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) ➤ Try a Free Trial RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for infliximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/044 United Kingdom ➤ Try a Free Trial PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526
2016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
0717 Netherlands ➤ Try a Free Trial PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
AstraZeneca
Boehringer Ingelheim
Chinese Patent Office
Moodys
Deloitte
McKinsey
Julphar
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.